Cellosaurus logo
expasy logo

Cellosaurus K562-rn (CVCL_DP55)

[Text version]
Cell line name K562-rn
Accession CVCL_DP55
Resource Identification Initiative To cite this cell line use: K562-rn (RRID:CVCL_DP55)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Tasigna).
Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
Disease Blast phase chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C9110)
Chronic myeloid leukemia (ORDO: Orphanet_521)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0004 (K-562)
Sex of cell Female
Age at sampling 53Y
Category Cancer cell line
Publications

PubMed=19047160; DOI=10.1158/0008-5472.CAN-08-1008
Mahon F.-X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., Belanger C., Manley P.W., Leroy C., Etienne G., Roche S., Pasquet J.-M.
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Cancer Res. 68:9809-9816(2008)

Cross-references
Encyclopedic resources Wikidata; Q54899400
Entry history
Entry creation13-Jul-2016
Last entry update02-May-2024
Version number15